Pretreatment with phosphatase and tensin homolog deleted on chromosome 10 (PTEN) inhibitor SF1670 augments the efficacy of granulocyte transfusion in a clinically relevant mouse model

Blood

Volumn 117, Issue 24, 2011, Pages 6702-6713

  Li, Yitang ^a   Prasad, Amit ^a   Jia, Yonghui ^a   Roy, Saurabh Ghosh ^a   Loison, Fabien ^a   Mondal, Subhanjan ^a   Kocjan, Paulina ^a   Silberstein, Leslie E ^a   Ding, Sheng ^b   Luo, Hongbo R ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOATTRACTANT; CYCLOPHOSPHAMIDE; ENZYME INHIBITOR; GRANULOCYTE COLONY STIMULATING FACTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SF 1670; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL LOAD; CELL TRANSPLANTATION; CHEMOTAXIS; CHROMOSOME DELETION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; ENZYME INHIBITION; GRANULOCYTE TRANSFUSION; INNATE IMMUNITY; MALE; MOUSE; NEUTROPENIA; NEUTROPHIL; NONHUMAN; PERITONEAL CAVITY; PHAGOCYTOSIS; PRIORITY JOURNAL; RESPIRATORY BURST; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION;

EID: 79959235806     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-09-309864     Document Type: Article

References (49)

1. Joos L, Tamm M. Breakdown of pulmonary host defense in the immunocompromised host: cancer chemotherapy. Proc Am Thorac Soc. 2005;2(5): 445-448. (Pubitemid 43128041)
2. Viscoli C, Varnier O, Machetti M. Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. Clin Infect Dis. 2005;40(suppl 4):S240-245.
3. Leung AN, Gosselin MV, Napper CH, et al. Pulmonary infections after bone marrow transplantation: clinical and radiographic findings. Radiology. 1999;210(3):699-710. (Pubitemid 29124030)
4. Anderlini P, Przepiorka D, Champlin R, Korbling M. Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals. Blood. 1996;88(8):2819-2825. (Pubitemid 26357361)
5. Hübel K, Dale DC, Liles WC. Granulocyte transfusion therapy: update on potential clinical applications. Curr Opin Hematol. 2001;8(3):161-164. (Pubitemid 32324637)
6. Briones MA, Josephson CD, Hillyer CD. Granulocyte transfusion: revisited. Curr Hematol Rep. 2003;2(6):522-527.
7. Price TH. Granulocyte transfusion: current status. Semin Hematol. 2007;44(1):15-23. (Pubitemid 46013926)
8. Strauss RG. Neutrophil transfusion therapy. In: Gabrilovich DI, ed. The Neutrophils: New Outlook for Old Cells. London, United Kingdom: Imperial College Press; 1999;345-362.
9. Herzig RH, Herzig GP, Graw RG Jr, Bull MI, Ray KK. Successful granulocyte transfusion therapy for gram-negative septicemia. A prospectively randomized controlled study. N Engl J Med. 1977;296(13):701-705. (Pubitemid 8066531)
10. Higby DJ, Yates JW, Henderson ES, Holland JF. Filtration leukapheresis for granulocyte transfusion therapy. Clinical and laboratory studies. N Engl J Med. 1975;292(15):761-766.
11. Vogler WR, Winton EF. A controlled study of the efficacy of granulocyte transfusions in patients with neutropenia. Am J Med. 1977;63(4):548-555. (Pubitemid 8214928)
12. Alavi JB, Root RK, Djerassi I, et al. A randomized clinical trial of granulocyte transfusions for infection in acute leukemia. N Engl J Med. 1977; 296(13):706-711. (Pubitemid 8066532)
13. Graw RG Jr, Herzig G, Perry S, Henderson ES. Normal granulocyte transfusion therapy: treatment of septicemia due to gram-negative bacteria. N Engl J Med. 1972;287(8):367-371.
14. Price TH, Bowden RA, Boeckh M, et al. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation. Blood. 2000;95(11): 3302-3309. (Pubitemid 30428457)
15. Hübel K, Carter RA, Liles WC, et al. Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors. Transfusion. 2002;42(11):1414-1421.
16. Nichols WG, Price TH, Gooley T, Corey L, Boeckh M. Transfusion- transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood. 2003;101(10):4195-4200. (Pubitemid 36857904)
17. Bokoch GM. Chemoattractant signaling and leukocyte activation. Blood. 1995;86(5):1649-1660.
18. Olson TS, Ley K. Chemokines and chemokine receptors in leukocyte trafficking. Am J Physiol Regul Integr Comp Physiol. 2002;283(1):R7-28.
19. Cantrell DA. Phosphoinositide 3-kinase signalling pathways. J Cell Sci. 2001;114(Pt 8):1439-1445. (Pubitemid 32427831)
20. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296(5573):1655-1657. (Pubitemid 34579158)
21. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489-501. (Pubitemid 37328931)
22. Rodgers EE, Theibert AB. Functions of PI 3-kinase in development of the nervous system. Int J Dev Neurosci. 20(3-5):187-197, 2002.
23. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006; 7(8):606-619. (Pubitemid 44100518)
24. Maehama T, Dixon JE. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol. 1999;9(4):125-128. (Pubitemid 29161437)
25. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell. 2000;100(4): 387-390.
26. Rauh MJ, Kalesnikoff J, Hughes M, Sly L, Lam V, Krystal G. Role of Src homology 2-containing-inositol 5′-phosphatase (SHIP) in mast cells and macrophages. Biochem Soc Trans. 2003; 31(Pt 1):286-291. (Pubitemid 36241446)
27. Zhu D, Hattori H, Jo H, et al. Deactivation of phosphatidylinositol 3,4,5-trisphosphate/Akt signaling mediates neutrophil spontaneous death. Proc Natl Acad Sci U S A. 2006;103(40):14836-14841. (Pubitemid 44527815)
28. Subramanian KK, Jia Y, Zhu D, et al. Tumor suppressor PTEN is a physiologic suppressor of chemoattractant-mediated neutrophil functions. Blood. 2007;109(9):4028-4037. (Pubitemid 46641758)
29. Li Y, Jia Y, Pichavant M, et al. Targeted deletion of tumor suppressor PTEN augments neutrophil function and enhances host defense in neutropenia-associated pneumonia. Blood. 2009; 113(20):4930-4941.
30. Rosivatz E, Matthews JG, McDonald NQ, et al. A small molecule inhibitor for phosphatase and tensin homologue deleted on chromosome 10 (PTEN). ACS Chem Biol. 2006;1(12):780-790.
31. Hattori H, Zhang X, Jia Y, et al. RNAi screen identifies UBE2D3 as a mediator of all-trans retinoic acid-induced cell growth arrest in human acute promyelocytic NB4 cells. Blood. 2007;110(2):640-650. (Pubitemid 47105403)
32. Garlich JR, Durden DL, Georgiadis TM, Su J, Peng X, Smith TC. Pten inhibitors. U.S. Patent Application 20070203098; 2007.
33. Jia Y, Subramanian KK, Erneux C, et al. Inositol 1,3,4,5- tetrakisphosphate negatively regulates phosphatidylinositol-3,4,5- trisphosphate signaling in neutrophils. Immunity. 2007;27(3):453-467. (Pubitemid 47432757)
34. Schmid AC, Byrne RD, Vilar R, Woscholski R. Bisperoxovanadium compounds are potent PTEN inhibitors. FEBS Lett. 2004;566(1-3):35-38. (Pubitemid 38625928)
35. Haugh JM, Codazzi F, Teruel M, Meyer T. Spatial sensing in fibroblasts mediated by 3′ phosphoinositides. J Cell Biol. 2000;151(6):1269-1280.
36. Servant G, Weiner OD, Herzmark P, Balla T, Sedat JW, Bourne HR. Polarization of chemoattractant receptor signaling during neutrophil chemotaxis. Science. 2000;287(5455):1037-1040. (Pubitemid 30094359)
37. Luo HR, Hattori H, Hossain MA, et al. Akt as a mediator of cell death. Proc Natl Acad Sci U S A. 2003;100(20):11712-11717. (Pubitemid 37206000)
38. Zigmond SH. Chemotactic response of neutrophils. Am J Respir Cell Mol Biol. 1989;1(6):451-453.
39. Ridley AJ, Schwartz MA, Burridge K, et al. Cell migration: integrating signals from front to back. Science. 2003;302(5651):1704-1709. (Pubitemid 37505725)
40. Gardiner EM, Pestonjamasp KN, Bohl BP, Chamberlain C, Hahn KM, Bokoch GM. Spatial and temporal analysis of Rac activation during live neutrophil chemotaxis. Curr Biol. 2002; 12(23):2029-2034. (Pubitemid 35450926)
41. Zigmond SH. Ability of polymorphonuclear leukocytes to orient in gradients of chemotactic factors. J Cell Biol. 1977;75(2 Pt 1):606-616. (Pubitemid 8205010)
42. Cao X, Wei G, Fang H, et al. The inositol 3-phosphatase PTEN negatively regulates Fc gamma receptor signaling, but supports Toll-like receptor 4 signaling in murine peritoneal macrophages. J Immunol. 2004;172(8):4851-4857. (Pubitemid 38456408)
43. Hallett MB, Lloyds D. Neutrophil priming: the cellular signals that say 'amber' but not 'green'. Immunol Today. 1995;16(6):264-268.
44. Swain SD, Rohn TT, Quinn MT. Neutrophil priming in host defense: role of oxidants as priming agents. Antioxid Redox Signal. 2002;4(1):69-83. (Pubitemid 34260688)
45. Walker BA, Ward PA. Priming and signal transduction in neutrophils. Biol Signals. 1992;1(5): 237-249.
46. Looney MR, Matthay MA. Animal models of transfusion-related acute lung injury. Crit Care Med. 2006;34(5 suppl):S132-136.
47. Yu H, Li Y, Gao C, et al. Relevant mouse model for human monocytic leukemia through Cre/lox-controlled myeloid-specific deletion of PTEN. Leukemia. 2010;24(5):1077-1080.
48. Liu Q, Sasaki T, Kozieradzki I, et al. SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation and myeloid cell survival. Genes Dev. 1999;13(7):786-791. (Pubitemid 29169837)
49. Luo HR, Huang YE, Chen JC, et al. Inositol pyrophosphates mediate chemotaxis in Dictyostelium via pleckstrin homology domain-PtdIns(3,4,5)P3 interactions. Cell. 2003;114(5):559-572. (Pubitemid 37159253)